Document is current

Article History

Received: 13 January 2026

Accepted: 21 January 2026

First Online: 9 February 2026

Declarations

:

: Funding: This work was supported by Allergy Therapeutics. Financial interests outside the submitted work: C Galan reports personal fees from Allergy Therapeutics Iberica. J Buters reports grants from Government of Bavaria, grants from Deutsche Forschungsgesellschaft, grants from Helmholtzzentrum Munich, personal fees from ALK-Abello, personal fees from HAL Allergy, personal fees from Novartis, personal fees from ThermoFisher, personal fees from Lofarma, personal fees from Stallergenes-Greer, personal fees from Allergopharma, personal fees from Philips, grants from European Union. C Bergmann reports personal fees from Allergy Therapeutics, Bencard, Astra Zeneca, GSK, HAL Allergy and SCS. M Cuevas reports personal fees from ALK-Abelló, Allergopharma, AstraZeneca, Bencard Allergie/ Allergy Therapeutics, Celltrion Healthcare Deutschland GmbH, GlaxoSmithKline, HAL Allergy, Leti Pharma, NeilMed, Novartis, Roxall, Sanofi-Aventis and Stallergenes. P Werminghaus reports personal fees from Astra Zeneca, Bencard Allergie, GSK, Sanofi and Stallergenes. E Jensen-Jarolim is the inventor of patent EP 2894478 A1 to immunoBON ® , owned by Biomedical Int. R+D GmbH, Vienna, Austria, of which she is shareholder. MF Kramer, S Hewings, M Skinner, H Young, A Graessel and M Feindor are stock holders of Allergy Therapeutics plc. Non-financial interests: none. Employment: S Hewings, J Goodman, H Young, D Hernandez, M Feindor, A Graessel, M Skinner and MF Kramer are employees of Allergy Therapeutics (UK) Ltd/Allergy Therapeutics Iberica/Bencard Allergie GmbH, a company providing AIT preparations including a 13-grass mix. P Huber, J Oteros and MM Sailer have no relevant financial or non-financial interests to disclose.